Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARS study: dapagliflozin safety after renal surgery in patients with renal dysfunction
jRCT1031220661Completed
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dapagliflozin in chronic kidney disease (CKD). Primary endpoint: Incidence of adverse events. Started May 2024; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT1031220661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220661.